William Scott, MD
Internal Medicine · Greeneville, TNNPI 1730116724
Payments from drug & device makers
Across 68 payments — averaging $25.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$396
- Pfizer$228
- Lilly USA, LLC$156
- Novo Nordisk$131
- AbbVie$123
- Ceribell, Inc.$111
- plus $558 from 17 others
What the payments were for
- Food & beverage$1,702100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 5 | $396 |
| Pfizer | 15 | $228 |
| Lilly USA, LLC | 6 | $156 |
| Novo Nordisk | 6 | $131 |
| AbbVie(2 entities) | 7 | $123 |
| Ceribell, Inc. | 1 | $111 |
| GSK | 6 | $92 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $69 |
| AstraZeneca | 3 | $60 |
| E.r. Squibb & Sons, L.L.C. | 2 | $35 |
| Sanara Medtech Inc. | 1 | $33 |
| Xeris Pharmaceuticals, Inc. | 2 | $33 |
| Exact Sciences | 2 | $32 |
| Johnson & Johnson | 2 | $28 |
| Phathom Pharmaceuticals, Inc. | 1 | $25 |
| Merck | 1 | $21 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $21 |
| Vanda Pharmaceuticals Inc. | 1 | $20 |
| Amneal Pharmaceuticals LLC | 1 | $20 |
| Bayer | 1 | $20 |
| Dynavax Technologies Corporation | 1 | $18 |
| Seqirus USA Inc | 1 | $17 |
| Abbott | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- POCKET EEG DEVICE$111
- JARDIANCE$100
How this compares
$1,702 in reported general payments places this provider in the 75th percentile of 2,216 internal medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 215 | $189,546 |
| MounjaroTirzepatide | 86 | $104,415 |
| JardianceEmpagliflozin | 113 | $101,352 |
| OzempicSemaglutide | 89 | $98,003 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 92 | $84,426 |
| XareltoRivaroxaban | 59 | $53,928 |
| JanuviaSitagliptin Phosphate | 62 | $49,336 |
| TrulicityDulaglutide | 24 | $32,658 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 18 | $16,006 |
| EntrestoSacubitril/Valsartan | 17 | $12,008 |
| Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp | 39 | $10,750 |
| FarxigaDapagliflozin Propanediol | 12 | $10,472 |
| Spiriva RespimatTiotropium Bromide | 15 | $8,652 |
| Emgality SyringeGalcanezumab-Gnlm | 12 | $7,932 |
| Tresiba Flextouch U-200Insulin Degludec | 13 | $7,446 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $228 | $189,546215 claims |
| Lilly USA, LLCMounjaro, Trulicity | $156 | $137,073110 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $396 | $110,003128 claims |
| Novo NordiskOzempic, Novolog | $131 | $104,270120 claims |
| GSKTrelegy Ellipta | $92 | $84,42692 claims |
| Johnson & JohnsonXarelto | $28 | $53,92859 claims |
| MerckJanuvia | $21 | $49,33662 claims |
| AstraZenecaFarxiga, Brilinta | $60 | $13,35423 claims |
| AbbVieLinzess, Synthroid | $123 | $8,03036 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $20 | $3,509482 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,216 internal medicine providers in Tennessee.
Other internal medicine in Greeneville
- Mark McKenzieChattanooga$11.9M
- Bernard GrunstraBristol$6.4M
- Jewel WhiteKingsport$5.7M
- Judith WhiteKingsport$5.6M
- Obadias MarquezOoltewah$2.8M
- Amanda Moore MillerKnoxville$2.3M
- Rick WhilesBristol$1.5M
- John AndersonNashville$1.5M
- David MorinKingsport$1.4M
- John KirbyJefferson City$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.